Altered expression of DACH1 and cyclin D1 in endometrial cancer

The altered expression of human DACH1, a Drosophila Dachshund homolog, has been associated with tumor progression and metastasis. DACH1 inhibits breast cancer cellular proliferation via cyclin D1. Endometrial cancer is the third most common cancer in women and broad screening for DACH1 expression will further our understanding of this disease. Herein, we screened 126 hysterectomy specimens for DACH1 expression and evaluated the correlation between DACH1 levels and several clinical parameters. Decreased DACH1 expression was significantly correlated with FIGO surgical stages (Stage I-II vs. stage III-IV, p=0.017), peritoneal cytology (p=0.044), lymph node positivity (p=0.035), and histological type (p=0.007), but not histological grade, depth of myometrial, and patient age. Immunostaining was also conducted to examine the expression of cyclin D1, estrogen receptor alpha (ERα) and progesterone receptor (PR) in these specimens. Multivariate analysis using the stepwise Cox proportional hazard model showed that FIGO surgical stage, histological grade, lymph node metastasis, and PR expression were correlated with poor survival. Despite the fact that univariate analysis demonstrated that DACH1 positivity is associated with increased 5-year survival in all patients (p=0.037), decreased expression of DACH1 had no significant value as an independent prognostic factor in predicting survival in endometrial cancers. Our results suggested that loss of DACH1 expression might be involved in endometrial cancer progression.

[1]  J. Baak,et al.  The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer. , 2009, American journal of obstetrics and gynecology.

[2]  T. Gotoda,et al.  Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples , 2008, Cancer science.

[3]  R. Scott,et al.  The influence of the Cyclin D1 870 G>A polymorphism as an endometrial cancer risk factor , 2008, BMC Cancer.

[4]  C. DeLisi,et al.  Identification of novel epigenetic markers for clear cell renal cell carcinoma. , 2008, The Journal of urology.

[5]  Anping Li,et al.  Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8 , 2008, Proceedings of the National Academy of Sciences.

[6]  M. Meyerson,et al.  HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. , 2008, International journal of oncology.

[7]  O. Olopade,et al.  An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[8]  Anping Li,et al.  Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. , 2007, Molecular biology of the cell.

[9]  M. Szmitkowski,et al.  [Tumor markers useful in the diagnostics and monitoring of endometrial and cervical cancer]. , 2007, Postepy higieny i medycyny doswiadczalnej.

[10]  G. Prendergast,et al.  Cyclin D1 Functions in Cell Migration , 2006, Cell cycle.

[11]  M. Lisanti,et al.  Cyclin D1 induction of cellular migration requires p27(KIP1). , 2006, Cancer research.

[12]  Ales Cvekl,et al.  DACH1 Is a Cell Fate Determination Factor That Inhibits Cyclin D1 and Breast Tumor Growth , 2006, Molecular and Cellular Biology.

[13]  S. Mok,et al.  Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. , 2006, Cancer research.

[14]  Anping Li,et al.  Cyclin D1 Regulates Cellular Migration through the Inhibition of Thrombospondin 1 and ROCK Signaling , 2006, Molecular and Cellular Biology.

[15]  C. Morrison,et al.  HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Hibshoosh,et al.  HER‐2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications , 2006, International Journal of Gynecologic Cancer.

[17]  J. Celestino,et al.  Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma , 2006, International Journal of Gynecologic Cancer.

[18]  N. Park,et al.  Cyclin D1 polymorphism and the risk of endometrial cancer. , 2005, Gynecologic oncology.

[19]  H. Kuramoto,et al.  Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis. , 2004, Anticancer research.

[20]  J. Cigudosa,et al.  Molecular alterations associated with cyclin d1 overexpression in endometrial cancer , 2004, International journal of cancer.

[21]  Chenguang Wang,et al.  Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential. , 2004, Cancer treatment and research.

[22]  A. Semczuk,et al.  Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features , 2004, Archives of Gynecology and Obstetrics.

[23]  G. Filiz,et al.  Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables , 2005, Archives of Gynecology and Obstetrics.

[24]  K. Leslie,et al.  Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  T. Nikaido,et al.  Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. , 2003, Human pathology.

[26]  Amanda Y. Chan,et al.  Cyclin D1 governs adhesion and motility of macrophages. , 2003, Molecular biology of the cell.

[27]  T. Maruo,et al.  Simultaneous immunohistochemical localization of beta-catenin and cyclin D1 in differentiated but not in undifferentiated human endometrial carcinoma. , 2003, European journal of gynaecological oncology.

[28]  R. Miranda,et al.  Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. , 2009, Archives of pathology & laboratory medicine.

[29]  L. Shum,et al.  Fibroblast growth factor signaling regulates Dach1 expression during skeletal development , 2002, Developmental dynamics : an official publication of the American Association of Anatomists.

[30]  M. Einstein,et al.  Expression of COX-2, Ki-67, Cyclin D1, and P21 in Endometrial Endometrioid Carcinomas , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[31]  T. Löning,et al.  Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters , 2001, Journal of Cancer Research and Clinical Oncology.

[32]  K. Milde-Langosch,et al.  Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators , 2001, Journal of Cancer Research and Clinical Oncology.

[33]  R. Soslow,et al.  Cyclin D1 Expression in High-Grade Endometrial Carcinomas—Association with Histologic Subtype , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[34]  G. Mardon,et al.  The retinal determination gene, dachshund, is required for mushroom body cell differentiation. , 2000, Development.

[35]  A. Brinkmann,et al.  Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method , 2000, British Journal of Cancer.

[36]  C. Cordon-Cardo,et al.  Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  N. Umesaki,et al.  The role of p16-cyclin D/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma , 2000, British Journal of Cancer.

[38]  M. Esteller,et al.  Advances in the molecular genetics of endometrial cancer (Review). , 1999, Oncology reports.

[39]  H. Sasano,et al.  Immunohistochemical study of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma. , 1998, Anticancer research.

[40]  P. Kubilis,et al.  Expression of HER-2/neu oncogene in normal, hyperplastic, and malignant endometrium. , 1998, Annals of clinical and laboratory science.

[41]  G. Mardon,et al.  Dachshund and Eyes Absent Proteins Form a Complex and Function Synergistically to Induce Ectopic Eye Development in Drosophila , 1997, Cell.

[42]  G. Mardon,et al.  Ectopic eye development in Drosophila induced by directed dachshund expression. , 1997, Development.

[43]  T. Nikaido,et al.  Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas , 1996, Cancer.

[44]  F. Nogales.  Prognostic factors in endometrial neoplasia: old and new. , 1996, Current opinion in obstetrics & gynecology.

[45]  G. Rubin,et al.  dachshund encodes a nuclear protein required for normal eye and leg development in Drosophila. , 1994, Development.

[46]  F. Bosch,et al.  PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. , 1994, Cancer research.

[47]  S. Cha,et al.  HER‐2/neu expression: A major prognostic factor in endometrial cancer , 1992, Gynecologic oncology.

[48]  H. Nyholm.  [Endometrial cancer and steroid hormone receptors]. , 1990, Ugeskrift for laeger.

[49]  S. Ingram,et al.  The predictive value of progesterone receptor levels in endometrial cancer. , 1989, International journal of radiation oncology, biology, physics.

[50]  A. Kauppila.  Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. , 1989, Acta oncologica.